SCHEMBL22307372

SCHEMBL22307372

CC(C)(C)OC(=O)NCCc1ccc(BOC(C)(C)C(C)(C)O)s1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.40
HTT P42858 1/20 0.38
NQO2 P16083 1/20 0.38
NAMPT P43490 1/20 0.38
TDP1 Q9NUW8 2/20 0.36
MAPT P10636 1/20 0.36
CA1 P00915 3/20 0.36
CA2 P00918 3/20 0.36
LMNA P02545 3/20 0.36
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
ALDH1A1 P00352 3/20 0.35
CA12 O43570 2/20 0.35
CA9 Q16790 2/20 0.35
GFER P55789 1/20 0.35
TSHR P16473 2/20 0.35
PKM P14618 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19190653 0.80 CA2 (0.47) HTTNQO2NAMPTTDP1MAPT
SCHEMBL22306558 0.77 HTT (0.44) NPSR1HTTNQO2NAMPTTDP1
SCHEMBL19770197 0.75 HTT (0.44) NPSR1HTTNQO2NAMPTTDP1
SCHEMBL30466794 0.74 HPGD (0.49) NPSR1HTTNQO2NAMPTTDP1
SCHEMBL19263488 0.73 CA12 (0.57) MAPTCA1CA2CA12CA9
SCHEMBL30466788 0.73 HTT (0.42) NPSR1HTTNQO2NAMPTTDP1
SCHEMBL17732865 0.72 L3MBTL1 (0.46) NPSR1NAMPTTDP1MAPTCA1
SCHEMBL30466778 0.72 MALT1 (0.43) NPSR1HTTNQO2NAMPTTDP1
SCHEMBL22290822 0.71 USP30 (0.44) NPSR1HTTNQO2NAMPTTDP1
SCHEMBL12461268 0.71 CA12 (0.58) TDP1CA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230029009-A1 CHEMICAL COMPOUNDS BLUE OWL CAPITAL CORPORATION, AS NEW AGENT 2023-01-26 US disclosed
US-20200270257-A1 Chemical Compounds BLUE OWL CAPITAL CORPORATION, AS NEW AGENT 2020-08-27 US disclosed
WO-2020160075-A1 CHEMICAL COMPOUNDS AVISTA PHARMA SOLUTIONS, INC. (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230029009-A1 CHEMICAL COMPOUNDS PTGER4, PTGES, PTGES2 NPSR1 124/4885HTT 4172/4885NQO2 1730/4885
US-20200270257-A1 Chemical Compounds PTGER4, PTGES, PTGES2 NPSR1 124/4885HTT 4172/4885NQO2 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.